These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2906088)

  • 41. [Schizophrenic deficit syndrome and neurologic tolerance].
    Verdoux H; Bourgeois M
    Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late onset involuntary movements in chronic schizophrenia: age-related vulnerability to 'tardive' dyskinesia independent of extent of neuroleptic medication.
    Waddington JL; Youssef HA
    Ir Med J; 1985 May; 78(5):143-6. PubMed ID: 2861172
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
    Glazer WM; Bowers MB; Charney DS; Heninger GR
    Biol Psychiatry; 1989 Jul; 26(3):224-33. PubMed ID: 2568132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of two iatrogenic dyskinesias.
    Karson CN; Jeste DV; LeWitt PA; Wyatt RJ
    Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
    Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction.
    Quinn J; Meagher D; Murphy P; Kinsella A; Mullaney J; Waddington JL
    Schizophr Res; 2001 Apr; 49(1-2):79-87. PubMed ID: 11343867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tardive dyskinesia and perceptual dysfunction.
    Donnelly EF; Jeste DV; Wyatt RJ
    Percept Mot Skills; 1981 Dec; 53(3):689-90. PubMed ID: 6119676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Involuntary disorders of movement in chronic schizophrenia--the role of the illness and its treatment.
    Owens DG
    Psychopharmacology Suppl; 1985; 2():79-87. PubMed ID: 2860663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of spontaneous dyskinesia in schizophrenia.
    Fenton WS
    J Clin Psychiatry; 2000; 61 Suppl 4():10-4. PubMed ID: 10739325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Psychopathology and cognitive disorders in chronic schizophrenic patients with tardive dyskinesia].
    Kaiser W
    Nervenarzt; 1989 Apr; 60(4):206-12. PubMed ID: 2566936
    [No Abstract]   [Full Text] [Related]  

  • 57. Syndromes of chronic schizophrenia and some clinical correlates.
    Brown KW; White T
    Br J Psychiatry; 1992 Sep; 161():317-22. PubMed ID: 1356571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of tardive dyskinesia with increased frequency of eye movement disturbances in chronic schizophrenic patients. A clinical note.
    Oepen G; Thoden U; Warmke C
    Eur Arch Psychiatry Neurol Sci; 1990; 239(4):241-5. PubMed ID: 1969345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Orofacial dyskinesia, cognitive function and medication.
    Thomas P; McGuire R
    Br J Psychiatry; 1986 Aug; 149():216-20. PubMed ID: 2877703
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.